The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Stem cells and neurological diseases
Open accessAbstract
Abstract. Cells of the central nervous system were once thought to be incapable of regeneration. This dogma has been challenged in the last decade with studies showing new, migrating stem cells in the brain in many rodent injury models and findings of new neurones in the human hippocampus in adults. Moreover, there are reports of bone marrow‐derived cells developing neuronal and vascular phenotypes and aiding in repair of injured brain. These findings have fuelled excitement and interest in regenerative medicine for neurological diseases, arguably the most difficult diseases to treat. There are numerous proposed regenerative approaches to neurological diseases. These include cell therapy approaches in which cells are delivered intracerebrally or are infused by an intravenous or intra‐arterial route; stem cell mobilization approaches in which endogenous stem and progenitor cells are mobilized by cytokines such as granulocyte colony stimulatory factor (GCSF) or chemokines such as SDF‐1; trophic and growth factor support, such as delivering brain‐derived neurotrophic factor (BDNF) or glial‐derived neurotrophic factor (GDNF) into the brain to support injured neurones; these approaches may be used together to maximize recovery. While initially, it was thought that cell therapy might work by a ‘cell replacement’ mechanism, a large body of evidence is emerging that cell therapy works by providing trophic or ‘chaperone’ support to the injured tissue and brain. Angiogenesis and neurogenesis are coupled in the brain. Increasing angiogenesis with adult stem cell approaches in rodent models of stroke leads to preservation of neurones and improved functional outcome. A number of stem and progenitor cell types has been proposed as therapy for neurological disease ranging from neural stem cells to bone marrow derived stem cells to embryonic stem cells. Any cell therapy approach to neurological disease will have to be scalable and easily commercialized if it will have the necessary impact on public health. Currently, bone marrow‐derived cell populations such as the marrow stromal cell, multipotential progenitor cells, umbilical cord stem cells and neural stem cells meet these criteria the best. Of great clinical significance, initial evidence suggests these cell types may be delivered by an allogeneic approach, so strict tissue matching may not be necessary. The most immediate impact on patients will be achieved by making use of the trophic support capability of cell therapy and not by a cell replacement mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matrix elasticity directs stem cell lineage specification
Engler, A. J., Sen, S., Sweeney, H. L., & Discher, D. E. (2006) · Cell · doi:10.1016/j.cell.2006.06.044 · Cited by 13,915
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Subventricular zone astrocytes are neural stem cells in the adult mammalian brain
Doetsch, F., Caillé, I., Lim, D. A., García-Verdugo, J. M., & Alvarez-Buylla, A. (1999) · Cell · doi:10.1016/s0092-8674(00)80783-7 · Cited by 3,898
Mesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992
Neuronal replacement from endogenous precursors in the adult brain after stroke
Arvidsson, A., Collin, T., Kirik, D., Kokaia, Z., & Lindvall, O. (2002) · Nature Medicine · doi:10.1038/nm747 · Cited by 2,799
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
The glial identity of neural stem cells
Doetsch, F. (2003) · Nature Neuroscience · doi:10.1038/nn1144 · Cited by 724
Cited by
Wei, L., Fraser, J. L., Lu, Z.-Y., Hu, X., & Yu, S. P. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.002 · Cited by 358
Exploring the role of stem cells in cutaneous wound healing
Lau, K., Paus, R., Tiede, S., Day, P., & Bayat, A. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.00942.x · Cited by 279
Differential Mobilization of Subsets of Progenitor Cells from the Bone Marrow
Pitchford, S. C., Furze, R. C., Jones, C. P., Wengner, A. M., & Rankin, S. M. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2008.10.017 · Cited by 277
Wei, X., Du, Z., Zhao, L., Feng, D., Wei, G., He, Y., Tan, J., Lee, W.-H., Hampel, H., Dodel, R., et al. (2009) · Stem Cells · doi:10.1634/stemcells.2008-0333 · Cited by 254
Mesenchymal stem cell‐based therapy: a new paradigm in regenerative medicine
Satija, N. K., Singh, V. K., Verma, Y. K., Gupta, P., Sharma, S., Afrin, F., Sharma, M., Sharma, P., Tripathi, R. P., & Gurudutta, G. U. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00857.x · Cited by 252
Metadata
- Authors
- Hess, D. C., & Borlongan, C. V.
- Venue
- Cell Proliferation
- Publisher
- Wiley
- Published
- 2007-12-20
- Volume
- 41
- Issue
- s1
- Pages
- 94-114
- ISSN
- 0960-7722 (ISSN-L)
- 1365-2184
- OpenAlex
- W1505870579
- Cited by
- 229
- References
- 7
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stem cells and neurological diseases. https://app.cochat.ai/papers/10.1111/j.1365-2184.2008.00486.x
- The paper
- Hess, D. C., & Borlongan, C. V. (2008). Stem cells and neurological diseases. Cell Proliferation. https://doi.org/10.1111/j.1365-2184.2008.00486.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.